This week, CVRX reported positive six-month trial results for its Barostim Neo, an FDA-approved treatment for heart failure.
The results follow years of close work between the agency and CVRx, one of the more ambitious startups in medtech. CVRx is targeting a huge clinical need with novel neuromodulation technology.
In this week’s DeviceTalks Weekly podcast, CEO Nadim Yared walks us through the negotiations the company went through with the FDA to get to this point.
Yared, the prior chairman of the industry group AdvaMed, also shares the story of his career, which started early on when he secured a job at GE even before graduating college.
In this talk, Yared speaks to several issues including:
- The power of confidence and the dangers of overconfidence when building a career.
- How he decided to take the job at CVRx (and why he didn’t initially want to talk about the job with a recruiter.)
- What CVRx learned from other successes and failures in renal denervation.
- Why the company is betting big on heart failure, but doesn’t have a Chief Medical Officer.
- Whether or not his role as chairman at AdvaMed impacted his work at CVRx.
- Can medtechs generate good returns after raising hundreds of millions in capital?
This conversation took place prior to the emergence of COVID-19, so DTW host Tom Salemi visited again with Yared more recently. We’ll play that interview in next week’s episode of DeviceTalks Weekly.
If you’re looking for more medtech discussions, register now for DeviceTalks Tuesday at devicetalks.com.
Subscribe to the podcast. Don’t miss an episode!